Ascentage Pharma Group International (NASDAQ:AAPG) Hits New 12-Month Low – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) hit a new 52-week low during mid-day trading on Thursday. The company traded as low as $14.55 and last traded at $14.6290, with a volume of 9357 shares traded. The stock had previously closed at $14.94.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on AAPG shares. BTIG Research reiterated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Down 3.0%

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The stock has a fifty day simple moving average of $16.83 and a two-hundred day simple moving average of $19.41.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million during the quarter. On average, research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.